Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 15, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

An update on corporate progress and reported third quarter financial results as of March 31, 2026 (Year end June 30).
May 14, 2026 08:30 ET | Source: GT Biopharma, Inc.

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

GTB-5550 is now the 3rd TriKE® to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose...
April 29, 2026 08:00 ET | Source: Tacalyx GmbH

Tacalyx Secures €11 Million to Advance Lead TACA-Targeting ADC Programme Toward the Clinic

Tacalyx Secures €11 Million to Advance Lead TACA-Targeting ADC Programme Toward the Clinic Berlin, Germany, April 29, 2026 (GLOBE NEWSWIRE) -- Tacalyx, a leader in the discovery and development of...
March 24, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

The goal is to strengthen our intellectual property and to better understand how PRP technology can overcome resistant tumors and age-related diseases.
March 12, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game.
March 10, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

The purpose of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to patients
March 10, 2026 04:30 ET | Source: Kainova Therapeutics

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

Kainova Therapeutics announces positive Phase I results for DT‑9081, showing strong safety, target engagement and early anti‑tumor activity.
February 12, 2026 04:00 ET | Source: Adlai Nortye Ltd.

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company...
February 05, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

As we advance toward human trials, we remain committed to delivering hope to patients facing limited options for aggressive cancers from solid tumors.
January 27, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Filing four provisional patent applications...underscores our relentless drive to protect and expand our groundbreaking proenzyme technology